Navigation Links
Many Prostate Cancers Will Not Need Treatment
Date:2/13/2008

Major study finds most older men will die of other causes

WEDNESDAY, Feb. 13 (HealthDay News) -- One of the largest studies of its kind concludes that most older men with early prostate cancer do not shorten their survival odds if they adopt a "wait-and-see" approach to the disease.

In fact, most such patients will die of other causes or they simply won't develop any complications from the cancer, the researchers found.

"Many elderly men with lower risk cancer may do well with conservative management," concluded study author Grace Lu-Yau, a cancer epidemiologist at the Cancer Institute of New Jersey, and an associate professor at UMDNJ-Robert Wood Johnson Medical School and School of Public Health.

"Each patient facing a treatment decision has to ask himself what is the potential survival benefit of various treatments and the potential side effects of various treatments, then compare this potential risk of side effects with the potential risk of cancer complications if the cancer is left untreated -- and ask themselves which treatment option is their personal preference," Lu-Yau said.

She presented the findings to reporters at a special teleconference Tuesday, part of the 2008 Genitourinary Cancers Symposium taking place in San Francisco.

The question of whether to treat or not treat prostate cancer has long absorbed experts.

Although one in six men in the United States will be diagnosed with prostate cancer in their lifetime, many of the malignancies are slow-growing, and there is currently no reliable way to identify which men will benefit from treatment. Better knowledge of the natural history of the disease (i.e., what happens without any treatment) would help guide treatment decisions, Lu-Yau said.

This study is one of the first to look at the natural history of prostate cancer since PSA (prostate-specific antigen) blood testing has become commonplace. PSA tests can detect a prostate cancer six to 13 years earlier than previous methods.

Lu-Yau and her colleagues looked at data on more than 9,000 men with Stage I or II prostate cancer diagnosed between 1992 and 2002 who did not undergo treatment. The mean age of participants was 77 years.

Seventy-two percent of these men died of other causes or didn't have enough cancer progression to warrant surgery or radiation, the researchers found. For the remaining 2,675 men who did receive treatment, the median time between diagnosis and start of therapy was more than 10 years.

Not surprisingly, men with less aggressive disease survived longer than those with more aggressive tumors.

"For elderly men with localized prostate cancer, the potential survival benefit for treatment is most likely modest, therefore it is very critical to weigh the risk of having side effects of various treatments with the risk of developing cancer-related complications down the road," Lu-Yau said. "The majority of patients will die of other causes or remain alive without significant major complications."

A second study presented at the conference found that giving salvage radiation therapy (SRT) to men whose PSA levels rise after having their prostate removed can reduce their risk of dying from the cancer by more than 60 percent.

SRT is typically given only after a recurrence, not after an initial diagnosis of prostate cancer, noted study lead author Dr. Bruce Trock, associate professor of urology, epidemiology, oncology and environmental health sciences at Johns Hopkins University School of Medicine in Baltimore. Existing studies have either not been large enough or long enough in duration to determine if SRT prolongs survival.

In this retrospective analysis of 635 men who had experienced a recurrence after having their prostate removed, 62 percent of those who did not receive any salvage therapy were still alive after 10 years, versus 86 percent of those who received SRT and 82 percent of those who received SRT plus hormone therapy.

Men whose PSA doubling time (the amount of time it took for PSA levels to double from when in first becomes detectable) was six months or less had the greatest benefit.

"If another study was able to replicate our data, it could lead to clinical trial that would eventually support a way to determine who should get immediate adjuvant radiation and who could wait until the time of recurrence to have SRT," Trock said. "The question is, could a benefit be achieved in some of these men if you waited to see whether they recurred or not?"

More information

There's more on prostate cancer at U.S. National Cancer institute.



SOURCES: Feb. 12, 2008, teleconference with Grace Lu-Yau, Ph.D., cancer epidemiologist, Cancer Institute of New Jersey and associate professor, UMDNJ-Robert Wood Johnson Medical School and School of Public Health, and Bruce Trock, M.D., associate professor, urology, epidemiology, oncology and environmental health sciences, Johns Hopkins University School of Medicine, Baltimore


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. GPS for the Prostate: System Keeps Radiation Therapy on Target
2. Whats good for the heart may be good for the prostate
3. Whats Good for the Heart May Be Good for the Prostate
4. Men who are continually active at work may have a decreased risk of prostate cancer
5. More Gene Variations Found That Raise Prostate Cancer Risk
6. U.S. Representatives Urge Critical Improvements in Prostate Cancer Detection
7. Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer
8. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
9. Men Can Take Their Time to Decide on Prostate Cancer Treatment, Reports the Harvard Mens Health Watch
10. Online tool supports more dialogue on prostate cancer risk
11. Experimental Vaccine Halts Prostate Cancer in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Many Prostate Cancers Will Not Need Treatment
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: